Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year ...

Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

The company reported a net loss of $825 million for the quarter. Additionally, Moderna announced a $300 million reduction at the high end of their 2025 projected revenue range due to a timing shift of ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, expectations were $-2.99. Operator: Good day, and thank you for standing by. Welcome ...

MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

The biotech company reported second-quarter financial results on Friday ahead of market open, a day after announcing plans to ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...